Key statistics
On Friday, Moleculin Biotech Inc (MBRX:NAQ) closed at 2.37, 12.06% above the 52 week low of 2.12 set on Aug 01, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.43 |
---|---|
High | 2.47 |
Low | 2.30 |
Bid | 2.30 |
Offer | 2.67 |
Previous close | 2.46 |
Average volume | 15.31k |
---|---|
Shares outstanding | 2.84m |
Free float | 2.72m |
P/E (TTM) | -- |
Market cap | 6.74m USD |
EPS (TTM) | -11.62 USD |
Data delayed at least 15 minutes, as of Sep 20 2024 21:00 BST.
More ▼
- Moleculin Participates in Virtual Investor "What this Means" Segment
- Moleculin Announces First Patients Treated in Phase 2 Clinical Trial of STAT3 Inhibitor in Combination with Radiation for the Treatment of Glioblastoma
- Moleculin to Present at the H.C. Wainwright 26th Annual Global Investment Conference
- Moleculin to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar
- Moleculin Announces Closing of up to $16.5 Million Public Offering
- Moleculin Announces Pricing of up to $16.5 Million Public Offering
- Moleculin Reports Second Quarter 2024 Financial Results and Provides Corporate Update
- Moleculin to Host Webcast Presentation to Discuss Recently Announced Plans for MIRACLE Phase 3 Pivotal Trial Tuesday, August 6, 2024 at 8:30 AM ET
- Moleculin Announces Plans for MIRACLE Phase 3 Pivotal Trial
- Moleculin Completes End of Phase 2 Meeting with FDA for Annamycin in AML
More ▼